Gritstone bio, Inc.

Gritstone bio, Inc. is a clinical-stage biotechnology company specializing in developing immunotherapies for various cancer types and infectious diseases. Its lead product candidate, GRANITE, is a neoantigen-based immunotherapy targeting solid tumors, including non-small cell lung cancer, gastroesophageal, bladder, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy for common solid tumors, and CORAL, a SARS-CoV-2 vaccine platform. Additionally, it is working on a therapeutic vaccine candidate for HIV. Gritstone bio, Inc. generates revenue through strategic collaborations with companies like bluebird bio, Inc. and Gilead Sciences, Inc., as well as through license agreements with partners like Genevant Sciences GmbH.

Products

• GRANITE (neoantigen-based immunotherapy)

• SLATE (off-the-shelf immunotherapy)

• CORAL (SARS-CoV-2 vaccine platform)

• Therapeutic vaccine candidate for HIV